Vernalis Share Discussion Threads

[tjacovou] 12/12/2006 10:41

There is a report in todays Independant re the start of the trials of Vernalis anti obesity drug. Sam Fazeli, an analyst at Piper Jaffray said the Berkshire based company has "added to a pipeline that is already pretty significant, one of the best in the sector". Could this be a good time to get in cheap?

[fhmktg] 11/12/2006 14:53

Just a small cheer for our company - another candidate off on its trials?

[jweekes] 08/12/2006 13:01

The frova agreement with Elan is as follows(in summary).
Key terms of the agreement are:

* $60m in unconditional payments to Vernalis comprising $30m license fee
payable upon closing of the transaction and two $15m payments on the
first and second anniversaries of closing.

* $50m, 5-year loan facility to be first used to repay Vernalis' obligation
to Elan

* $40m milestone on FDA approval of the use of Frova(TM) as a prophylactic
treatment for MAM, which is currently in Phase III clinical development.

* Up to $255m in sales milestones based on increasing net sales targets
starting with a milestone of $10m on $200m net annual sales.

* Tiered royalties of 20% and higher on sales following FDA approval of the
MAM indication.

* Significant and immediate investment by Endo in the sales and marketing
for Frova(TM) for acute migraine treatment and, if approved, for
MAM.

[jweekes] 08/12/2006 11:00

since my last post I have been looking into the possibility of frova causing birth defects. The good news is that there have been no cases of increased birth abnormalities seen during the extensive trials, or in the population using the drug. In fact it seems that the incidence of birth defects is actually lower for women on frova than for those on many other meds.

Frova could be an enormous moneymaker for vernalis and is in my opinion highly likely to be approved for menstrual migraine in just a few months time. There's also the hefty milestone payment due to vernalis ($180?) upon approval.

I can see the share price running up to the £1 mark in the next month or so based on speculation alone. £2 plus after approval.

[liveit2] 06/12/2006 21:26

with a handle like that - I would have thought you could keep yourself together and not panic -

[4screws] 05/12/2006 22:27

what the hell is goin on now, thats an unusual drop at close of play, does someone know something that we obviously don't

[liveit2] 04/12/2006 20:42

bulls winning

[jweekes] 01/12/2006 23:31

Sumatriptan (generic version of GSK's Imigran, produced by ACTAVIS)is replacing Imigran due to its lower cost. I believe that GPs must inform all patients when a current treatment is altered by the GP. Short term this probably will have a negative impact on frova's sales but the massive potential of frova is in menstrual-associated migraine, for which Vernalis have a long patent protection.

They sent your wife that letter because you have a good GP. My surgery has an A4 letter stapled to a door stating the fact to anyone who may happen to notice it.

fhmktg - there was very little new in the webcast. Follow the links in the rns for the slides and comentary, registration required.

[rayrac] 01/12/2006 18:05

My wife's doctors surgery have just advised her by letter that they are stopping using Imigran and now will dispence Sumatriptan. Does that mean they can now use generic versions or other company's products, eg, Vernalis's Frova?

How will that affect Frova', positive or neg'?

Why did they bother to send that advice to my wife?

[fhmktg] 01/12/2006 13:14

I missed the presentation, last evening - any comments?

[jweekes] 30/11/2006 22:42

Point taken fickena - thanks. I just get a bit nervous when this hits the upper 50's. If it holds I'll be topping up.

[fickena] 29/11/2006 12:32

Not really as most drugs cause severe side effects in animals as they do not state what doses. Sometimes it is hundreds of times the recommended dose.

They have to place these warnings, as if a patient takes 100 tablets they can sue stating that they didn't know. This way it shifts blame onto the doctor for prescribing the drug.

Ibuprofen (a drug recomended for menstrual pain) is an over the counter drug and available to all and carries even stiffer warnings about birth defects.

[jweekes] 29/11/2006 12:11

Its from the US National Institutes of Health:

Frovatriptan has not been studied in pregnant women. However, studies in animals have shown that frovatriptan causes birth defects. Before taking this medicine, make sure your doctor knows if you are pregnant or if you may become pregnant.

[adgd2] 29/11/2006 11:41

your source?

[jweekes] 29/11/2006 11:20

Frovatriptan causes birth defects in animal models. And this is being pushed as a treatment for menstrual migraines? I very much hope frova doesn't become a new thalidomide.

[rfinance] 21/11/2006 20:34

Master RSI,

Your comments are always welcome but why do you repeat news that appears on the Recent News section of this board?

[master rsi] 21/11/2006 12:00

Further news of CEO being presentat next week Healthcare Conference

21 November 2006

Vernalis plc to Present at the 18th Annual Piper Jaffray Healthcare Conference
in New York on November 30, 2006

WINNERSH, U.K., November 21, 2006 -- Vernalis plc (LSE: VER, Nasdaq: VNLS), a
specialty bio-pharmaceutical and drug development company, today announced that
Simon Sturge, Chief Executive Officer, will present at the 18th Annual Piper
Jaffray Healthcare Conference to be held November 29, 2006 through December 1,
2006 at The Pierre Hotel in New York City. Mr. Sturge is scheduled to present an
overview of the Company's business activities and product pipeline at 4:30 PM
Eastern time on Thursday, November 30, 2006.

Investors may access a live webcast of the presentation at www.vernalis.com
under the Investor Relations tab. The presentation will be accessible for 30
days after the event.

[master rsi] 20/11/2006 17:52

lets see if tomorrow is a better day, cos the news did not doo much good...

Novartis selects Vernalis' second cancer drug candidate under joint R&D prog
LONDON (AFX) - Drug development company Vernalis PLC said Swiss pharma major
Novartis AG has approved a second compound, discovered through Vernalis'
platform, as a preclinical development candidate under its joint cancer research
and development programme.
It said it will get a milestone payment of 1.5 mln usd from Novartis as part
of the three-year collaboration agreement entered in August 2004 under which
Novartis provides research funding, clinical testing and commercialisation
facilities to drugs discovered by Vernalis.
It said the second candidate is used for inhibition of heat shock protein 90
(Hsp90) as an oral follow on to an intra-venous compound.
"Inhibition of Hsp90 is receiving increasing attention as a novel anticancer
treatment with broad therapeutic potential for the treatment of patients with
both solid tumours and haematologic cancers," Vernalis said, adding its Novartis
collaboration is delivering "exciting new cancer treatment opportunities".

[fhmktg] 20/11/2006 09:19

Another small, but positive announcement from Fellner's team.
What's likely to be the announcement which would start the share price upwards - apart from a takeover!

[liveit2] 16/11/2006 20:33

Not long now

[master rsi] 16/11/2006 13:22

60.25 - 61p +0.50p

maybe this time is for the turn

[adgd2] 15/11/2006 15:44

there's an analysts article on the global pain market here

[maysun] 10/11/2006 09:25

Good company, a solid medium term multi-bagger investment........LOL!!!

[rhtshah2] 10/11/2006 08:05

Good value says today's IC.

[master rsi] 02/11/2006 21:19

And today the third day share price rising, good volume once again